MCID: OVR013
MIFTS: 30

Ovarian Mucinous Cystadenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Mucinous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Mucinous Cystadenocarcinoma:

Name: Ovarian Mucinous Cystadenocarcinoma 12 54 15 17
Mucinous Cystadenocarcinoma of Ovary 12 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3604
NCIt 49 C4026
SNOMED-CT 67 254851009
UMLS 71 C0279665

Summaries for Ovarian Mucinous Cystadenocarcinoma

Disease Ontology : 12 An ovarian cystadenocarcinoma that is characterized by the presence of mucin.

MalaCards based summary : Ovarian Mucinous Cystadenocarcinoma, also known as mucinous cystadenocarcinoma of ovary, is related to spindle cell sarcoma and cystadenocarcinoma. An important gene associated with Ovarian Mucinous Cystadenocarcinoma is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways is Homologous DNA Pairing and Strand Exchange. The drugs Cisplatin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and liver.

Related Diseases for Ovarian Mucinous Cystadenocarcinoma

Diseases related to Ovarian Mucinous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 spindle cell sarcoma 30.8 VIM SERPINA3
2 cystadenocarcinoma 30.7 VIM SERPINA3 FSHR CEACAM5
3 mucinous cystadenocarcinoma 30.7 VIM SERPINA3 FSHR CEACAM5
4 mucinous adenocarcinoma 30.6 VIM CEACAM5
5 epulis 30.5 VIM SERPINA3
6 embryonal sarcoma 30.5 VIM SERPINA3
7 ovarian mucinous adenocarcinoma 30.2 SERPINA3 CEACAM5
8 cystadenoma 30.2 SERPINA3 CEACAM5
9 endodermal sinus tumor 30.1 VIM CEACAM5
10 ovarian cystadenocarcinoma 30.0 SERPINA3 CEACAM5
11 cystic teratoma 10.4
12 teratoma 10.4
13 sarcoma 10.3
14 pseudomyxoma peritonei 10.3
15 appendix adenocarcinoma 10.3
16 ovarian cyst 10.3
17 ovarian mucinous neoplasm 10.3
18 lymphangiomatosis 10.3 VIM PCNA
19 odontoma 10.3 VIM PCNA
20 intravascular papillary endothelial hyperplasia 10.3 VIM SERPINA3
21 congenital epulis 10.3 VIM SERPINA3
22 cystic lymphangioma 10.2 SERPINA3 PCNA
23 ovarian cancer 10.2
24 zollinger-ellison syndrome 10.2
25 multicentric reticulohistiocytosis 10.2 VIM SERPINA3
26 odontogenic myxoma 10.2 VIM SERPINA3
27 meningioma, radiation-induced 10.2 VIM PCNA
28 gingival hypertrophy 10.2 VIM SERPINA3
29 epithelioid leiomyosarcoma 10.2 VIM SERPINA3
30 congenital fibrosarcoma 10.2 VIM SERPINA3
31 pleomorphic liposarcoma 10.2 VIM SERPINA3
32 adenosarcoma 10.2 VIM SERPINA3
33 pseudosarcomatous fibromatosis 10.2 VIM SERPINA3
34 fibroma 10.2 VIM SERPINA3
35 cutaneous fibrous histiocytoma 10.2 VIM SERPINA3
36 fibrous histiocytoma 10.2 VIM SERPINA3
37 pigmented villonodular synovitis 10.2 VIM SERPINA3
38 lung giant cell carcinoma 10.2 VIM SERPINA3
39 granular cell tumor 10.2 VIM SERPINA3
40 trophoblastic neoplasm 10.2 SERPINA3 PCNA
41 hemangiopericytoma, malignant 10.1 VIM SERPINA3
42 smooth muscle tumor 10.1 VIM SERPINA3
43 ovarian benign neoplasm 10.1 FSHR CEACAM5
44 endometrial cancer 10.1
45 small cell carcinoma 10.1
46 filariasis 10.1
47 filarial elephantiasis 10.1
48 neuroendocrine carcinoma 10.1
49 breast cancer 10.1
50 multiple endocrine neoplasia, type i 10.1

Graphical network of the top 20 diseases related to Ovarian Mucinous Cystadenocarcinoma:



Diseases related to Ovarian Mucinous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Mucinous Cystadenocarcinoma

Drugs & Therapeutics for Ovarian Mucinous Cystadenocarcinoma

Drugs for Ovarian Mucinous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
2
Bevacizumab Approved, Investigational Phase 3 216974-75-3
3
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
4
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7 Antineoplastic Agents, Immunological Phase 3
8 Angiogenesis Inhibitors Phase 3
9 Tubulin Modulators Phase 2, Phase 3
10 Antimitotic Agents Phase 2, Phase 3
11 Albumin-Bound Paclitaxel Phase 2, Phase 3
12 Immunologic Factors Phase 3
13 Alkylating Agents Phase 3
14 Immunosuppressive Agents Phase 3
15 Antirheumatic Agents Phase 3
16 Analgesics Phase 3
17
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
18
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
19
Lenograstim Approved, Investigational Phase 2 135968-09-1
20
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
21
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
22
Liposomal doxorubicin Phase 2 31703
23 Anti-Bacterial Agents Phase 2
24 Antibiotics, Antitubercular Phase 2
25 topoisomerase I inhibitors Phase 2
26
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
27 Protein Kinase Inhibitors Phase 1, Phase 2
28 Antimetabolites Phase 2
29
Thiotepa Approved, Investigational Phase 1 52-24-4 5453
30
Melphalan Approved Phase 1 148-82-3 460612 4053
31
Iodine Approved, Investigational Phase 1 7553-56-2 807
32
Pancrelipase Approved, Investigational Phase 1 53608-75-6
33
Etoposide Approved Phase 1 33419-42-0 36462
34 Vaccines Phase 1
35 Antibodies Phase 1
36 Antibodies, Monoclonal Phase 1
37 Immunoglobulins Phase 1
38 pancreatin Phase 1
39 Immunotoxins Phase 1
40 Immunoglobulins, Intravenous Phase 1
41 Liver Extracts Phase 1
42 Etoposide phosphate Phase 1
43 Cola

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
2 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
3 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
6 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
7 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
8 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
9 A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
10 LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY Completed NCT00002538 Phase 2
11 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
12 Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
13 A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
14 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
15 A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum Terminated NCT00354601 Phase 2 capecitabine;docetaxel
16 A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
17 A Phase I Trial of Combination Carboplatin and Lipsomal Doxorubicin (Doxil) In Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
18 A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
19 A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
20 A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer Completed NCT00002977 Phase 1 melphalan;thiotepa
21 A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
22 A Dose Seeking Trial of Topotecan Combined With High-Dose Cyclophosphamide and Carboplatin With Peripheral Blood Stem Cell Transplant for the Treatment of Relapsed Ovarian Cancer and Primary Peritoneal Cancer Completed NCT00652691 Phase 1 carboplatin;cyclophosphamide;topotecan hydrochloride
23 Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Completed NCT00408590 Phase 1
24 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
25 Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days Completed NCT00006981 Phase 1
26 A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
27 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
28 A Phase I Study of Liposomal Doxorubicin (Doxil) and Prolonged Etoposide As Second Line Therapy in Ovarian, Tubal and Peritoneal Carcinoma Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
29 Non-invasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis by Quantitative Real Time MEMO-PCR Unknown status NCT02130648
30 Pelvic Mass Study to Develop Serum Proteomic Profiles (SIGNATURES) for Epithelial Ovarian Cancer Diagnosis and Prognosis Unknown status NCT00238342
31 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Unknown status NCT00897039
32 Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol Terminated NCT00904514

Search NIH Clinical Center for Ovarian Mucinous Cystadenocarcinoma

Genetic Tests for Ovarian Mucinous Cystadenocarcinoma

Anatomical Context for Ovarian Mucinous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Mucinous Cystadenocarcinoma:

40
Ovary, T Cells, Liver, Bone Marrow, Bone, Testes, Breast

Publications for Ovarian Mucinous Cystadenocarcinoma

Articles related to Ovarian Mucinous Cystadenocarcinoma:

(show top 50) (show all 79)
# Title Authors PMID Year
1
Effects of antisense oligodeoxynucleotide to follicle-stimulating hormone receptor on the cell proliferation and apoptosis in cells derived from human ovarian mucinous cystadenocarcinoma in Vitro. 54 61
17393121 2007
2
Effects of antisense oligodeoxynucleotide to follicle-stimulating hormone receptor on the expression of proliferating cell nuclear antigen and vascular endothelial growth factor in primary culture cells derived from human ovarian mucinous cystadenocarcinoma. 61 54
16711022 2006
3
Incidental detection of microfilaria in cyst fluid of Mucinous cystadenocarcinoma of ovary: A rare case report. 61
32416487 2020
4
A 35 Year Old Bangladeshi Lady with Hereditary Mucinous Ovarian Cancer, Complicated with Omental Metastasis. 61
31086172 2019
5
[Mucinous cystadenocarcinoma of ovary associated with neuroendocrine carcinoma (Primary ovarian pulmonary-type small cell carcinoma): report of a case]. 61
29783809 2018
6
Fertility preservation and refreezing of transplanted ovarian tissue-a potential new way of managing patients with low risk of malignant cell recurrence. 61
28433369 2017
7
Mucinous cystadenocarcinoma of ovary with metastasis in 14-year-old girl. 61
28344967 2017
8
Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature Cystic Teratoma: A Rare Case Report. 61
29927186 2016
9
Palliative Surgical Approach in Advanced Nonresponsive Mucinous Ovarian Cancer: A Rare Case Report. 61
27162429 2016
10
Giant mucinous cystadenocarcinoma of ovary: A case report and review of literature. 61
27134482 2016
11
Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors. 61
26400304 2015
12
The construction of cDNA library and the screening of related antigen of ascitic tumor cells of ovarian cancer. 61
26513889 2015
13
Melioidosis presenting as pseudomyxoma peritonei: yet another pretense of the great mimicker: an unreported entity. 61
23965152 2013
14
Retraction. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. 61
22706874 2012
15
LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. 61
22586057 2012
16
Neoplastic transformation of endocervicosis into an extraovarian mucinous cystadenocarcinoma. 61
21237491 2011
17
Magnetic resonance imaging and positron emission tomography of a giant multiseptated pyomyoma simulating an ovarian cancer. 61
20381038 2010
18
Gingival metastasis of ovarian carcinoma: report of a case and review of the literature. 61
19505797 2009
19
Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy. 61
19205713 2009
20
An ovarian mucinous cystadenocarcinoma arising from mature cystic teratoma with para-aortic lymph node metastasis: a case report. 61
19471656 2008
21
Mucinous metaplasia of breast carcinoma with macrocystic transformation resembling ovarian mucinous cystadenocarcinoma in a case of synchronous bilateral infiltrating ductal carcinoma. 61
18801076 2008
22
Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report). 61
19246966 2008
23
Cryptococcosis masquerading as a tuboovarian abscess. 61
18156972 2008
24
Triple simultaneous primary gynecological malignancies in a 56-year-old patient. 61
17009998 2006
25
Ovarian mucinous cystadenocarcinoma of low malignant potential associated with a mature cystic teratoma. 61
16951785 2006
26
[Endometrioid adenocarcinoma of the uterine cervix associated with mucinous ovarian cystadenocarcinoma]. 61
16677843 2006
27
Anaplastic carcinoma arising in an ovarian mucinous cystadenocarcinoma in a 17-year-old female. 61
16472728 2006
28
Ovarian mucinous cystadenocarcinoma of low malignant potential presented as a paraneoplastic skin lesion. 61
16234167 2005
29
Ovarian mucinous cystadenocarcinoma with mural nodule of anaplastic carcinoma and synchronous cervical squamous carcinoma. 61
15966336 2005
30
Splenectomy for solitary splenic metastasis of ovarian cancer. 61
15615591 2004
31
Chemotherapy for ovarian mucinous cystadenocarcinoma during pregnancy: a case report. 61
15493185 2004
32
Choroidal metastases from a primary ovarian mucinous cystadenocarcinoma. 61
12707607 2003
33
Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary. 61
12703547 2002
34
Co-existent ovarian mucinous cystadenocarcinoma and ovarian choriocarcinoma. 61
12192487 2002
35
Ovarian mucinous cystadenocarcinoma with virilization. 61
11855891 2002
36
[Establishment and characterization of a cell line derived from human ovarian mucinous cystadenocarcinoma]. 61
11718030 2001
37
[Multiple cavitary pulmonary metastases from ovarian cancer: a case report]. 61
11530393 2001
38
Virilization during pregnancy caused by ovarian mucinous cystadenocarcinoma. 61
11328230 2001
39
Ovarian mucinous cystadenocarcinoma as a cause of Zollinger-Ellison syndrome: report of a case and review of the literature. 61
10811352 2000
40
Ovarian mucinous cystadenocarcinoma with yolk sac tumor in a 71-year-old woman. 61
12090598 1999
41
Ovarian mucinous cystadenocarcinoma with malignant mural nodules. 61
9736414 1998
42
Ovarian mucinous cystadenocarcinoma with sarcoma-like mural nodules. 61
8624893 1996
43
Hyperestrogenemia and presence of estrogen receptors associated with an epithelial ovarian tumor of low malignant potential. 61
8856299 1996
44
Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin. 61
8522263 1995
45
An intraperitoneal tumorous mass caused by granulomas of microfibrillar collagen hemostat (Avitene). 61
7503666 1995
46
Establishment of OVS1 and OVS2 monoclonal antibodies recognizing human ovarian mucinous cystadenocarcinoma. 61
7488344 1995
47
[A case of ovarian mucinous cystadenocarcinoma in a young woman after treatment of dysgerminoma on opposite side]. 61
7775822 1995
48
Ovarian mucinous cystadenocarcinoma with sarcoma-like mural nodules. 61
7534853 1995
49
Cytogenetic changes in ovarian mucinous cystadenocarcinoma of low malignant potential with persistent pseudomyxoma peritonei. 61
7889512 1995
50
Expression of gonadotropin-releasing hormone receptor in human epithelial ovarian carcinoma. 61
7880073 1994

Variations for Ovarian Mucinous Cystadenocarcinoma

Expression for Ovarian Mucinous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Mucinous Cystadenocarcinoma.

Pathways for Ovarian Mucinous Cystadenocarcinoma

Pathways related to Ovarian Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.1 RMI2 RMI1 PCNA

GO Terms for Ovarian Mucinous Cystadenocarcinoma

Biological processes related to Ovarian Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA replication GO:0006260 8.8 RMI2 RMI1 PCNA

Sources for Ovarian Mucinous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....